Hologic, Inc. $HOLX Shares Sold by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale lowered its position in Hologic, Inc. (NASDAQ:HOLX) by 5.3% during the 2nd quarter, Holdings Channel.com reports. The firm owned 1,475,379 shares of the medical equipment provider’s stock after selling 82,661 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in Hologic were worth $96,123,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the company. Chung Wu Investment Group LLC acquired a new position in shares of Hologic during the second quarter valued at approximately $26,000. Zions Bancorporation National Association UT acquired a new position in shares of Hologic during the first quarter valued at approximately $34,000. Cromwell Holdings LLC increased its stake in shares of Hologic by 307.0% during the second quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider’s stock valued at $38,000 after acquiring an additional 436 shares during the period. Allworth Financial LP increased its stake in shares of Hologic by 46.0% during the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock valued at $40,000 after acquiring an additional 216 shares during the period. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new position in shares of Hologic during the first quarter valued at approximately $42,000. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Stock Performance

NASDAQ:HOLX opened at $71.87 on Tuesday. Hologic, Inc. has a 1 year low of $51.90 and a 1 year high of $84.39. The firm’s fifty day simple moving average is $67.19 and its 200 day simple moving average is $63.62. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $15.99 billion, a PE ratio of 29.82, a PEG ratio of 2.40 and a beta of 0.63.

Hologic (NASDAQ:HOLX) last posted its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same period last year, the business posted $1.06 EPS. Hologic’s revenue was up 1.2% compared to the same quarter last year. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, sell-side analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Citigroup upgraded shares of Hologic from a “neutral” rating to a “buy” rating and raised their price objective for the company from $60.00 to $80.00 in a research note on Wednesday, July 9th. Morgan Stanley raised their price objective on shares of Hologic from $65.00 to $69.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 31st. Royal Bank Of Canada upgraded shares of Hologic from a “sector perform” rating to an “outperform” rating and raised their price target for the company from $72.00 to $87.00 in a report on Wednesday, August 6th. Weiss Ratings restated a “hold (c-)” rating on shares of Hologic in a report on Wednesday, October 8th. Finally, Mizuho set a $75.00 price target on shares of Hologic in a report on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $80.15.

Insider Transactions at Hologic

In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of the firm’s stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the sale, the chief executive officer directly owned 1,234,624 shares in the company, valued at $82,682,769.28. This trade represents a 10.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 1.88% of the stock is owned by corporate insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.